BR112012018500A2 - alguns inibidores de quinurenina-3-monooxigenase, composições farmacêuticas e métodos de uso destas - Google Patents
alguns inibidores de quinurenina-3-monooxigenase, composições farmacêuticas e métodos de uso destasInfo
- Publication number
- BR112012018500A2 BR112012018500A2 BR112012018500A BR112012018500A BR112012018500A2 BR 112012018500 A2 BR112012018500 A2 BR 112012018500A2 BR 112012018500 A BR112012018500 A BR 112012018500A BR 112012018500 A BR112012018500 A BR 112012018500A BR 112012018500 A2 BR112012018500 A2 BR 112012018500A2
- Authority
- BR
- Brazil
- Prior art keywords
- methods
- pharmaceutical compositions
- chemical entity
- certain
- administering
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/30—Halogen atoms or nitro radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
Abstract
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US29809510P | 2010-01-25 | 2010-01-25 | |
PCT/US2011/021890 WO2011091153A1 (en) | 2010-01-25 | 2011-01-20 | Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112012018500A2 true BR112012018500A2 (pt) | 2016-08-16 |
Family
ID=44307208
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112012018500A BR112012018500A2 (pt) | 2010-01-25 | 2011-01-20 | alguns inibidores de quinurenina-3-monooxigenase, composições farmacêuticas e métodos de uso destas |
Country Status (14)
Country | Link |
---|---|
US (1) | US8883785B2 (pt) |
EP (1) | EP2528441A4 (pt) |
JP (1) | JP2013518046A (pt) |
KR (1) | KR20120131161A (pt) |
CN (1) | CN102811620B (pt) |
AU (1) | AU2011207229B2 (pt) |
BR (1) | BR112012018500A2 (pt) |
CA (1) | CA2787365A1 (pt) |
MX (1) | MX2012008346A (pt) |
NZ (1) | NZ601547A (pt) |
RU (1) | RU2012133475A (pt) |
SG (1) | SG182534A1 (pt) |
WO (1) | WO2011091153A1 (pt) |
ZA (1) | ZA201206223B (pt) |
Families Citing this family (60)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20110230428A1 (en) * | 2008-07-22 | 2011-09-22 | John Wityak | Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof |
JP5693452B2 (ja) | 2008-08-04 | 2015-04-01 | シーエイチディーアイ ファウンデーション,インコーポレーテッド | 特定のキヌレニン−3−モノオキシゲナーゼインヒビター、医薬組成物およびそれらの使用方法 |
AU2011207229B2 (en) | 2010-01-25 | 2015-02-12 | Chdi Foundation, Inc. | Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof |
JP2012041325A (ja) * | 2010-08-23 | 2012-03-01 | Bayer Cropscience Ag | オキサジアゾリノン誘導体およびその有害生物の防除用途 |
EP2635278B1 (en) | 2010-11-03 | 2019-12-11 | Dow AgroSciences LLC | Pesticidal compositions and processes related thereto |
US20140031547A1 (en) * | 2010-12-14 | 2014-01-30 | Electrophoretics Limited | CASEIN KINASE 1delta (CK 1delta) INHIBITORS AND THEIR USE IN THE TREATMENT OF NEURODE-GENERATIVE DISEASES SUCH AS TAUOPATHIES |
CA2841981A1 (en) * | 2011-07-28 | 2013-01-31 | Chdi Foundation, Inc. | Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof |
KR102027287B1 (ko) * | 2011-08-30 | 2019-10-01 | 씨에이치디아이 파운데이션, 인코포레이티드 | 키뉴레닌-3-모노옥시게나제 억제제, 약학적 조성물 및 이의 사용 방법 |
CN103827095A (zh) | 2011-08-30 | 2014-05-28 | Chdi基金会股份有限公司 | 犬尿氨酸-3-单加氧酶抑制剂、其药物组合物及其使用方法 |
US9200001B2 (en) * | 2011-10-06 | 2015-12-01 | Merck Sharp & Dohme Corp. | Triazolyl PDE10 inhibitors |
JP6027128B2 (ja) | 2011-10-26 | 2016-11-16 | ダウ アグロサイエンシィズ エルエルシー | 有害生物防除組成物およびそれに関連した方法 |
US9282739B2 (en) | 2012-04-27 | 2016-03-15 | Dow Agrosciences Llc | Pesticidal compositions and processes related thereto |
US9708288B2 (en) | 2012-04-27 | 2017-07-18 | Dow Agrosciences Llc | Pesticidal compositions and processes related thereto |
WO2013162716A2 (en) | 2012-04-27 | 2013-10-31 | Dow Agrosciences Llc | Pesticidal compositions and processes related thereto |
HUE039473T2 (hu) * | 2013-03-14 | 2019-01-28 | Curadev Pharma Private Ltd | Kinurenin útvonal inhibitorok |
GB201312800D0 (en) | 2013-07-17 | 2013-08-28 | Heptares Therapeutics Ltd | mGlu5 modulators |
KR20160074543A (ko) | 2013-10-17 | 2016-06-28 | 다우 아그로사이언시즈 엘엘씨 | 살충성 화합물의 제조 방법 |
CA2925954A1 (en) | 2013-10-17 | 2015-04-23 | Dow Agrosciences Llc | Processes for the preparation of pesticidal compounds |
US9102654B2 (en) | 2013-10-17 | 2015-08-11 | Dow Agrosciences Llc | Processes for the preparation of pesticidal compounds |
KR20160074540A (ko) | 2013-10-17 | 2016-06-28 | 다우 아그로사이언시즈 엘엘씨 | 살충성 화합물의 제조 방법 |
MX2016004941A (es) | 2013-10-17 | 2016-06-28 | Dow Agrosciences Llc | Proceso para la preparacion de compuestos plaguicidas. |
KR20160074542A (ko) | 2013-10-17 | 2016-06-28 | 다우 아그로사이언시즈 엘엘씨 | 살충성 화합물의 제조 방법 |
US9108946B2 (en) | 2013-10-17 | 2015-08-18 | Dow Agrosciences Llc | Processes for the preparation of pesticidal compounds |
TW201519774A (zh) | 2013-10-22 | 2015-06-01 | Dow Agrosciences Llc | 協同性殺蟲組成物及相關方法(六) |
US9497966B2 (en) | 2013-10-22 | 2016-11-22 | Dow Agrosciences Llc | Pesticidal compositions and related methods |
MX2016005324A (es) | 2013-10-22 | 2016-08-12 | Dow Agrosciences Llc | Composiciones pesticidas y metodos relacionados. |
US9137998B2 (en) | 2013-10-22 | 2015-09-22 | Dow Agrosciences Llc | Pesticidal compositions and related methods |
AU2014340438B2 (en) | 2013-10-22 | 2017-09-07 | Dow Agrosciences Llc | Synergistic pesticidal compositions and related methods |
CA2926647A1 (en) | 2013-10-22 | 2015-04-30 | Dow Agrosciences Llc | Pesticidal compositions and related methods |
AR098103A1 (es) | 2013-10-22 | 2016-05-04 | Dow Agrosciences Llc | Composiciones pesticidas y métodos relacionados |
KR20160074633A (ko) | 2013-10-22 | 2016-06-28 | 다우 아그로사이언시즈 엘엘씨 | 상승작용적 살충 조성물 및 관련 방법 |
AU2014340416B2 (en) | 2013-10-22 | 2017-09-07 | Dow Agrosciences Llc | Synergistic pesticidal compositions and related methods |
AU2014340413B2 (en) | 2013-10-22 | 2017-09-07 | Dow Agrosciences Llc | Synergistic pesticidal compositions and related methods |
EP3060051A4 (en) | 2013-10-22 | 2017-04-05 | Dow AgroSciences LLC | Synergistic pesticidal compositions and related methods |
AU2014340430B2 (en) | 2013-10-22 | 2017-05-25 | Dow Agrosciences Llc | Pesticidal compositions and related methods |
WO2015061142A1 (en) | 2013-10-22 | 2015-04-30 | Dow Agrosciences Llc | Synergistic pesticidal compositions and related methods |
MX2016005304A (es) | 2013-10-22 | 2017-03-01 | Dow Agrosciences Llc | Composiciones pesticidas sinergicas y metodos relacionados. |
RU2016119553A (ru) | 2013-10-22 | 2017-12-04 | ДАУ АГРОСАЙЕНСИЗ ЭлЭлСи | Синергетические пестицидные композиции и связанные с ними способы |
TW201519772A (zh) | 2013-10-22 | 2015-06-01 | Dow Agrosciences Llc | 協同性殺蟲組成物及相關方法(四) |
WO2015061170A1 (en) | 2013-10-22 | 2015-04-30 | Dow Agrosciences Llc | Synergistic pesticidal compositions and related methods |
GB201322512D0 (en) | 2013-12-19 | 2014-02-05 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
EP3119756B9 (en) * | 2014-03-19 | 2021-08-25 | Dow AgroSciences LLC | 2-(2,4-difluorophenyl)-1,1-difluoro-1-(5-substituted-pyridin-2-yl)-3-(1h-tetrazol-1-yl)propan-2-ols and processes for their preparation |
WO2016011316A1 (en) | 2014-07-17 | 2016-01-21 | Chdi Foundation, Inc. | Methods and compositions for treating hiv-related disorders |
EP3174856A4 (en) | 2014-07-31 | 2018-01-10 | Dow AgroSciences LLC | Process for the preparation of 3-(3-chloro-1h-pyrazol-1-yl)pyridine |
US9029556B1 (en) | 2014-07-31 | 2015-05-12 | Dow Argosciences Llc | Process for the preparation of 3-(3-chloro-1H-pyrazol-1-yl)pyridine |
EP3186230A4 (en) | 2014-07-31 | 2018-01-10 | Dow AgroSciences, LLC | Process for the preparation of 3-(3-chloro-1h-pyrazol-1-yl)pyridine |
WO2016028328A1 (en) | 2014-08-19 | 2016-02-25 | Dow Agrosciences Llc | Process for the preparation of 3-(3-chloro-1h-pyrazol-1-yl)pyridine |
CN107074775A (zh) | 2014-09-12 | 2017-08-18 | 美国陶氏益农公司 | 3‑(3‑氯‑1h‑吡唑‑1‑基)吡啶的制备方法 |
JP6644790B2 (ja) * | 2014-12-19 | 2020-02-12 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドGlaxosmithkline Intellectual Property Development Limited | キヌレニンモノオキシゲナーゼ阻害剤として有用な3−(6−アルコキシ−5−クロロベンゾ[d]イソキサゾール−3−イル)プロパン酸 |
GB201508864D0 (en) | 2015-05-22 | 2015-07-01 | Glaxosmithkline Ip Dev Ltd | Compounds |
GB201508857D0 (en) | 2015-05-22 | 2015-07-01 | Glaxosmithkline Ip Dev Ltd | Compounds |
JP2019533676A (ja) | 2016-10-13 | 2019-11-21 | ジュノー セラピューティクス インコーポレイテッド | トリプトファン代謝経路調節剤を含む免疫療法の方法および組成物 |
WO2018118781A1 (en) * | 2016-12-20 | 2018-06-28 | Fmc Corporation | Fungicidal oxadiazoles |
BR112019008372B1 (pt) | 2016-12-29 | 2021-11-09 | Dow Agrosciences Llc | Processo para preparação de compostos pesticidas |
CN110325036B (zh) | 2016-12-29 | 2021-10-26 | 美国陶氏益农公司 | 用于制备杀虫化合物的方法 |
WO2018220762A1 (ja) * | 2017-05-31 | 2018-12-06 | 大塚製薬株式会社 | ピリミジン化合物 |
CN111886501A (zh) * | 2018-03-19 | 2020-11-03 | 富士胶片和光纯药株式会社 | 精神疾病的判断方法 |
JP6870064B2 (ja) * | 2018-11-30 | 2021-05-12 | 大塚製薬株式会社 | ピリミジン化合物の医薬用途 |
TW202039446A (zh) | 2018-11-30 | 2020-11-01 | 日商大塚製藥股份有限公司 | 雜環化合物 |
US11911376B2 (en) | 2020-03-30 | 2024-02-27 | The Regents Of The University Of Colorado | Methods for preventing and treating retinal damage |
Family Cites Families (66)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3707560A (en) * | 1970-10-05 | 1972-12-26 | Pfizer | Certain 4-amino-6-aryl-pyrimidines |
GB8417852D0 (en) * | 1984-07-13 | 1984-08-15 | Fujisawa Pharmaceutical Co | Pyrimidine derivatives |
ZA868491B (en) * | 1985-11-09 | 1987-07-29 | Bayer Ag | Nicotinic acid derivatives |
DE3623302A1 (de) * | 1985-11-09 | 1987-05-14 | Bayer Ag | Nicotinsaeurederivate |
DE3609596A1 (de) * | 1986-03-21 | 1987-10-01 | Hoechst Ag | 2-azolylmethyl-2-aryl-1,3-dioxolane und deren salze, verfahren zu ihrer herstellung, sie enthaltende mittel und ihre verwendung |
MX16687A (es) | 1988-07-07 | 1994-01-31 | Ciba Geigy Ag | Compuestos de biarilo y procedimiento para su preparacion. |
AU644159B2 (en) * | 1990-05-17 | 1993-12-02 | Novartis Ag | 2-anilino-4-cyanopyrimidine derivatives |
DE4031798A1 (de) * | 1990-10-08 | 1992-04-09 | Hoechst Ag | Pyridylpyrimidine, verfahren zu ihrer herstellung, sie enthaltende mittel und ihre verwendung als fungizide |
DE19600934A1 (de) * | 1996-01-12 | 1997-07-17 | Basf Ag | Substituierte Aza- und Diazacycloheptan- und Cyclooctanverbindungen und deren Verwendung |
US6610723B2 (en) | 2001-01-29 | 2003-08-26 | Hoffmann-La Roche Inc. | Imidazole derivatives |
US6552188B2 (en) | 2001-06-29 | 2003-04-22 | Kowa Co., Ltd. | Unsymmetrical cyclic diamine compound |
AR037233A1 (es) | 2001-09-07 | 2004-11-03 | Euro Celtique Sa | Piridinas aril sustituidas, composiciones farmaceuticas y el uso de dichos compuestos para la elaboracion de un medicamento |
US6949542B2 (en) | 2002-02-06 | 2005-09-27 | Hoffman-La Roche Inc. | Dihydro-benzo[b][1,4]diazepin-2-one derivatives |
CN1703395A (zh) | 2002-08-09 | 2005-11-30 | 特兰斯泰克制药公司 | 芳基和杂芳基化合物以及调节凝血的方法 |
AU2003280558A1 (en) | 2002-10-11 | 2004-05-04 | Kowa Co., Ltd. | Method for treatment of cancer |
TWI335913B (en) * | 2002-11-15 | 2011-01-11 | Vertex Pharma | Diaminotriazoles useful as inhibitors of protein kinases |
JP2006514043A (ja) * | 2002-12-20 | 2006-04-27 | ファルマシア・コーポレーション | マイトジェン活性化タンパク質キナーゼ−活性化タンパク質キナーゼ−2を阻害する化合物 |
US20060293339A1 (en) * | 2003-03-24 | 2006-12-28 | Chakravarty Prasun K | Biaryl substituted 6-membered heterocycles as sodium channel blockers |
SE0301963D0 (sv) | 2003-07-02 | 2003-07-02 | Astrazeneca Ab | New compounds |
MXPA06001002A (es) | 2003-07-25 | 2006-04-11 | Amgen Inc | Piridonas y pirimidinonas sustituidas con propiedades antiinflamatorias. |
JPWO2005040135A1 (ja) | 2003-10-24 | 2007-03-08 | 小野薬品工業株式会社 | 抗ストレス薬およびその医薬用途 |
WO2005042498A2 (en) | 2003-10-31 | 2005-05-12 | Neurogen Corporation | 4-amino (aza) quinoline derivatives as capsaicin receptor agonists |
DK1763517T3 (da) | 2004-06-28 | 2011-06-06 | Hoffmann La Roche | Pyrimidinderivater som 11beta-HSD1-inhibitorer |
WO2006021458A2 (en) * | 2004-08-27 | 2006-03-02 | Gpc Biotech Ag | Pyrimidine derivatives |
ES2331579T3 (es) | 2004-08-27 | 2010-01-08 | Astellas Pharma Inc. | Derivado de 2-fenilpiridina. |
RU2394021C2 (ru) | 2004-12-07 | 2010-07-10 | Тояма Кемикал Ко., Лтд. | Новое производное антраниловой кислоты или его соль |
US20060178388A1 (en) * | 2005-02-04 | 2006-08-10 | Wrobleski Stephen T | Phenyl-substituted pyrimidine compounds useful as kinase inhibitors |
US7468383B2 (en) | 2005-02-11 | 2008-12-23 | Cephalon, Inc. | Proteasome inhibitors and methods of using the same |
AU2006223070B2 (en) | 2005-03-14 | 2012-02-09 | High Point Pharmaceuticals, Llc | Benzazole derivatives, compositions, and methods of use as B-secretase inhibitors |
EP1909910A1 (en) | 2005-08-04 | 2008-04-16 | Sirtris Pharmaceuticals, Inc. | Benzimidazole derivatives as sirtuin modulators |
EP1912970A2 (en) | 2005-08-10 | 2008-04-23 | Bayer Schering Pharma Aktiengesellschaft | Acyltryptophanols for fertility control |
CA2619101A1 (en) | 2005-08-23 | 2007-03-01 | Irm Llc | Immunosuppressant compounds and compositions |
TW200745055A (en) * | 2005-09-23 | 2007-12-16 | Organon Nv | 4-Phenyl-6-substituted-pyrimidine-2-carbonitrile derivatives |
US20090227588A1 (en) | 2005-12-05 | 2009-09-10 | Roman Wolfgang Fleck | Substituted pyrazole compounds useful as soluble epoxide hyrolase inhibitors |
EP1966141A1 (en) | 2005-12-14 | 2008-09-10 | Brystol-Myers Squibb Company | Six-membered heterocycles useful as serine protease inhibitors |
US7951824B2 (en) | 2006-02-17 | 2011-05-31 | Hoffman-La Roche Inc. | 4-aryl-pyridine-2-carboxyamide derivatives |
JP2007230963A (ja) | 2006-03-03 | 2007-09-13 | Daiso Co Ltd | 2,4−ジ置換ピリジンの製造法 |
JP5151045B2 (ja) * | 2006-03-13 | 2013-02-27 | コニカミノルタホールディングス株式会社 | 有機エレクトロルミネッセンス素子、表示装置及び照明装置 |
LT3357911T (lt) | 2006-06-26 | 2022-08-10 | Akebia Therapeutics Inc. | Prolilo hidroksilazės inhibitoriai ir naudojimo būdai |
EP2054397B1 (en) * | 2006-08-16 | 2015-10-07 | The J. David Gladstone Institutes, A Testamentary Trust Established under The Will of J. David Gladstone | Small molecule inhibitors of kynurenine-3-monooxygenase |
US8071631B2 (en) * | 2006-08-16 | 2011-12-06 | The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone | Small molecule inhibitors of kynurenine-3-monooxygenase |
WO2008023720A1 (fr) | 2006-08-23 | 2008-02-28 | Astellas Pharma Inc. | COMPOSÉ D'URÉE OU SEL DUDIT COMPOSé |
US8188113B2 (en) | 2006-09-14 | 2012-05-29 | Deciphera Pharmaceuticals, Inc. | Dihydropyridopyrimidinyl, dihydronaphthyidinyl and related compounds useful as kinase inhibitors for the treatment of proliferative diseases |
JP2008074751A (ja) * | 2006-09-20 | 2008-04-03 | Taiho Yakuhin Kogyo Kk | フェニルピリミジン化合物又はその塩、及びその用途 |
JP2008218986A (ja) * | 2007-02-06 | 2008-09-18 | Sumitomo Chemical Co Ltd | 組成物及び該組成物を用いてなる発光素子 |
WO2008095852A1 (en) | 2007-02-08 | 2008-08-14 | Respiratorius Ab | Bronchorelaxing arylamides |
JP2010523579A (ja) | 2007-04-02 | 2010-07-15 | インスティテュート フォア ワンワールド ヘルス | Cftr阻害剤化合物およびそれらの使用 |
EP2002834A1 (de) | 2007-06-13 | 2008-12-17 | Bayer Schering Pharma Aktiengesellschaft | Aryl/Hetarylamide als Modulatoren des EP2-Rezeptors |
AR067354A1 (es) | 2007-06-29 | 2009-10-07 | Sunesis Pharmaceuticals Inc | Compuestos utiles como inhibidores de la raf quinasa |
US20090163508A1 (en) * | 2007-10-10 | 2009-06-25 | Takeda Pharmaceutical Company Limited | Amide compound |
PE20091309A1 (es) | 2007-12-21 | 2009-09-30 | Astrazeneca Ab | Derivados de ciclohexilo como inhibidores de acetil coenzima a carboxilasa |
JP2009280521A (ja) | 2008-05-22 | 2009-12-03 | Daiso Co Ltd | 2,4−ジ置換ピリジンの製造法 |
JP2011184298A (ja) | 2008-06-02 | 2011-09-22 | Sanwa Kagaku Kenkyusho Co Ltd | 新規化合物及びその医薬用途 |
EP2321274A1 (en) | 2008-07-08 | 2011-05-18 | Boehringer Ingelheim International GmbH | Pyrrolidinyl and piperidinyl compounds useful as nhe-1 inhibitors |
JP5693452B2 (ja) * | 2008-08-04 | 2015-04-01 | シーエイチディーアイ ファウンデーション,インコーポレーテッド | 特定のキヌレニン−3−モノオキシゲナーゼインヒビター、医薬組成物およびそれらの使用方法 |
WO2010064597A1 (ja) * | 2008-12-01 | 2010-06-10 | 武田薬品工業株式会社 | ピペリジン誘導体 |
WO2010100475A1 (en) | 2009-03-02 | 2010-09-10 | Astrazeneca Ab | Hydroxamic acid derivatives as gram-negative antibacterial agents |
US8415378B2 (en) | 2009-04-07 | 2013-04-09 | Astrazeneca Ab | Isoxazol-3(2H)-one analogs as therapeutic agents |
US20120041009A1 (en) * | 2009-05-18 | 2012-02-16 | Sumitomo Chemical Company, Limited | Pyrimidine compound and its use in pest control |
TWI491606B (zh) | 2009-07-13 | 2015-07-11 | Gilead Sciences Inc | 調節細胞凋亡信號之激酶的抑制劑 |
US8859776B2 (en) | 2009-10-14 | 2014-10-14 | Merck Sharp & Dohme Corp. | Substituted piperidines that increase p53 activity and the uses thereof |
EP3492483A1 (en) | 2009-10-22 | 2019-06-05 | The Washington University | Compounds and methods for treating bacterial infections |
AU2011207229B2 (en) | 2010-01-25 | 2015-02-12 | Chdi Foundation, Inc. | Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof |
RS56312B1 (sr) | 2010-02-27 | 2017-12-29 | Bayer Ip Gmbh | Ariltriazoloni spojeni sa bis-arilom i njihova upotreba |
MX2012015105A (es) | 2010-07-02 | 2013-05-28 | Gilead Sciences Inc | Inhibidores de cinasa de regulacion mediante señal de apoptosis. |
KR20130056345A (ko) | 2010-09-17 | 2013-05-29 | 퍼듀 퍼머 엘피 | 피리딘 화합물 및 그의 용도 |
-
2011
- 2011-01-20 AU AU2011207229A patent/AU2011207229B2/en not_active Expired - Fee Related
- 2011-01-20 MX MX2012008346A patent/MX2012008346A/es not_active Application Discontinuation
- 2011-01-20 CA CA2787365A patent/CA2787365A1/en not_active Abandoned
- 2011-01-20 BR BR112012018500A patent/BR112012018500A2/pt not_active IP Right Cessation
- 2011-01-20 SG SG2012052189A patent/SG182534A1/en unknown
- 2011-01-20 JP JP2012550116A patent/JP2013518046A/ja active Pending
- 2011-01-20 CN CN201180015784.XA patent/CN102811620B/zh not_active Expired - Fee Related
- 2011-01-20 WO PCT/US2011/021890 patent/WO2011091153A1/en active Application Filing
- 2011-01-20 RU RU2012133475/04A patent/RU2012133475A/ru not_active Application Discontinuation
- 2011-01-20 EP EP11735184.1A patent/EP2528441A4/en not_active Withdrawn
- 2011-01-20 NZ NZ601547A patent/NZ601547A/en not_active IP Right Cessation
- 2011-01-20 US US13/575,019 patent/US8883785B2/en active Active
- 2011-01-20 KR KR1020127021570A patent/KR20120131161A/ko not_active Application Discontinuation
-
2012
- 2012-08-17 ZA ZA2012/06223A patent/ZA201206223B/en unknown
Also Published As
Publication number | Publication date |
---|---|
NZ601547A (en) | 2014-04-30 |
MX2012008346A (es) | 2012-11-12 |
AU2011207229B2 (en) | 2015-02-12 |
JP2013518046A (ja) | 2013-05-20 |
CA2787365A1 (en) | 2011-07-28 |
EP2528441A4 (en) | 2013-07-10 |
ZA201206223B (en) | 2013-04-24 |
WO2011091153A1 (en) | 2011-07-28 |
KR20120131161A (ko) | 2012-12-04 |
AU2011207229A1 (en) | 2012-08-16 |
CN102811620A (zh) | 2012-12-05 |
US20130029988A1 (en) | 2013-01-31 |
EP2528441A1 (en) | 2012-12-05 |
CN102811620B (zh) | 2015-03-25 |
SG182534A1 (en) | 2012-08-30 |
US8883785B2 (en) | 2014-11-11 |
RU2012133475A (ru) | 2014-03-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112012018500A2 (pt) | alguns inibidores de quinurenina-3-monooxigenase, composições farmacêuticas e métodos de uso destas | |
BR112014004845A2 (pt) | pelo menos uma entidade química; pelo menos um composto; composição farmacêutica; uso de uma quantidade terapeuticamente eficaz de pelo menos uma entidade química; composição farmacêutica embalada | |
BR112014004741A2 (pt) | pelo menos uma entidade química; composição farmacêutica; uso de uma quantidade terapeuticamente eficaz de pelo menos uma entidade química; composição farmacêutica embalada | |
EP2331095A4 (en) | CYNURENINE-3-MONOOXYGENASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND METHOD OF USE THEREOF | |
AU2012286851A8 (en) | Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof | |
EA202091999A3 (ru) | Применение ингибиторов dpp iv | |
EA200971053A1 (ru) | Способы лечения кожных язв | |
BR112015001419A2 (pt) | composto, composição farmacêutica, e, métodos para inibir romk em um paciente, para causar diurese, natriurese ou ambos e para tratamento de um ou mais distúrbios | |
BRPI0610321B8 (pt) | imidazoquinolinas como inibidores de lipídeo cinase, seu uso e seu processo de preparação, e preparação farmacêutica | |
BR112014016672A2 (pt) | compostos de carbamato e sua preparação e uso | |
BRPI0516177B8 (pt) | oligorribonucleotídeos, uso dos mesmos, uso de um composto sirna eficaz para inibir 0 p53 humano e composição farmacêutica que os contém, bem como método para diminuição da expressão do gene p53 | |
BR112015029918A2 (pt) | uso de alta dose de pridopidina para tratar a doença de huntington | |
BR112015029491A2 (pt) | derivados de imidazopirrolidinona e seu uso no tratamento de doença | |
BRPI0509172A (pt) | pelo menos uma entidade quìmica, composição farmacêutica, métodos para tratar um paciente, para inibir pelo menos uma enzima que utiliza atp, e para tratar pelo menos uma doença, uso de pelo menos uma entidade quìmica, e, método para a fabricação de um medicamento | |
EA200800798A1 (ru) | Фармацевтические композиции, предназначенные для лечения нарушений внутреннего уха | |
EA201590835A1 (ru) | Составы с низкой дозой панкрелипазы и кишечнорастворимым покрытием | |
EA201491606A1 (ru) | Ингибиторы кинуренин-3-монооксигеназы, фармацевтические композиции и способы их применения | |
BRPI0712322A2 (pt) | compostos e combinações destes para a inibição da produção de beta-amilóide e métodos de uso dos mesmos | |
BR112014018485A8 (pt) | Uso de laquinimod para tratar pacientes com a doença de crohn que falharam com a primeira linha de terapia anti-tnf | |
BR112012030641A2 (pt) | métodos e composições para terapia farmacêutica oral | |
BR112013010829B8 (pt) | Composição farmacêutica intravenosa para proporcionar alívio da dor e/ou da inflamação | |
EA201401231A1 (ru) | Фармацевтические комбинации, предназначенные для лечения метаболических нарушений | |
BR112021024886A2 (pt) | Métodos de tratar a doença de fabry em pacientes com insuficiência renal | |
EA200600921A1 (ru) | Способы и композиции с применением талидомида для лечения и менеджмента рака и других заболеваний | |
Yang et al. | Galangin inhibits LPS-induced MMP-9 expression via suppressing protein kinase-dependent AP-1 and FoxO1 activation in rat brain astrocytes |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B15I | Others concerning applications: loss of priority |
Free format text: PERDA DA PRIORIDADE US 61/298,095 DE 25/01/2010 REIVINDICADA NO PCT/US2011/021890 POR NAO APRESENTACAO DE COPIA DO CORRESPONDENTE DOCUMENTO DE CESSAO DENTRO DO PRAZO LEGAL DE 60 DIAS APOS A PETICAO DE ENTRADA NA FASE NACIONAL DO BRASIL CONFORME AS DISPOSICOES PREVISTAS NA LEI 9.279 DE 14/05/1996 (LPI) ART. 16 6O, ITEM 27 DO ATO NORMATIVO 128/97 E NO ART. 28 DA RESOLUCAO INPI-PR 77/2013 UMA VEZ QUE DEPOSITANTE CONSTANTE DA PETICAO DE REQUERIMENTO DO PEDIDO PCT E DISTINTO DAQUELE QUE DEPOSITOU A PRIORIDADE REIVINDICADA. |
|
B08F | Application fees: application dismissed [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 6A ANUIDADE. |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2394 DE 22-11-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |
|
B350 | Update of information on the portal [chapter 15.35 patent gazette] |